Considering the increasing use of anti-PD-1 immunotherapy in nonmetastatic NPC patients, this study aims to illustrate the incidence and clinical course of immune-related thyroid dysfunction and its role as a predictor of survival in nonmetastatic NPC. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.